The US Food and Drug Administration (FDA) has broadened the approval of Furoscix® (furosemide injection) to treat edema in ...

HC Wainwright reissued their buy rating on shares of scPharmaceuticals (NASDAQ:SCPH – Free Report) in a research note issued to investors on Thursday morning,Benzinga reports. The firm currently has a ...

Scpharmaceuticals (($SCPH)) has held its Q4 earnings call. Read on for the main highlights of the call. The recent earnings call for ...

Shares Outstanding: 50,095,689 as of December 31, 2024. scPharmaceuticals Inc (NASDAQ:SCPH) reported a significant increase ...

Q4 2024 Management View CEO John Tucker highlighted FUROSCIX's Q4 2024 net revenue of $12.2 million, which aligns with the previously announced range of $12 million to $12.3 million. For the full year ...

Pharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 millionCash and cash ...

Reports Q4 revenue $12.2M, consensus $12.18M..Reports Net FUROSCIX revenue of $12.2m and $36.3mfor the fourth quarter and full year 2024, ...

Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with ...

Furoscix is expected to be available for CKD patients in April 2025. The Food and Drug Administration (FDA) has expanded the approval of Furoscix ® (furosemide injection) to include the treatment ...